Key Updates
British American Tobacco has declined -2.30% since the last report to £4,381, moderating YTD gains to +3.96% from the previous +6.41%. The retreat follows strong 2025 financial results that exceeded expectations, with pretax profit surging to £9.86 billion and adjusted operating profit reaching £11.89 billion. However, the stock faces headwinds from ongoing legal challenges related to North Korean sanctions violations and competitive pressures in the U.S. nicotine pouch market, despite Velo gaining market share. The company's efforts to combat illegal vape sales through ITC proceedings show promise but face delayed implementation until 2027.
Current Trend
BATS.L maintains a modest positive YTD performance of +3.96%, though momentum has weakened considerably from the +9.37% peak reached in early February. The stock has experienced heightened volatility, declining -5.49% in one session before recovering +2.94%, and now retreating -2.30% following earnings release. The 6-month performance of +3.37% closely mirrors YTD gains, indicating limited medium-term momentum. Recent price action shows the stock trading at £4,381, with the 5-day performance of -4.95% suggesting near-term selling pressure despite strong fundamental results. The current consolidation phase reflects market digestion of mixed signals from robust earnings offset by competitive and legal concerns.
Investment Thesis
The investment thesis centers on BAT's successful transformation from traditional tobacco to next-generation products while maintaining robust cash generation from its legacy business. The company's new categories revenue reached £3.62 billion in 2025, growing 7% at constant currencies, demonstrating traction in vapor, heated products, and oral pouches. Velo's market share gains in the U.S. against Philip Morris's Zyn validate BAT's competitive positioning in the high-growth nicotine pouch segment. The company generates approximately 80% of revenue from traditional cigarettes, providing substantial cash flows to fund transformation and support a 2% dividend increase to 245.04 pence per share. However, the thesis faces challenges from a 75% illicit cigarette market in South Africa forcing factory closure, approximately 70% illegal vape penetration in the U.S., and significant legal liabilities from the $629 million North Korean sanctions settlement and ongoing terrorism-related lawsuits.
Thesis Status
The investment thesis remains partially validated but faces increased execution risks. The positive elements are firmly intact: adjusted operating profit of £11.89 billion exceeded consensus forecasts of £11.29 billion, new categories grew 7%, and Velo gained U.S. market share through higher nicotine strengths and promotional strategies. However, three significant challenges have emerged that temper the outlook. First, the South Africa factory closure by year-end 2026 represents a material operational retreat in a key market where illicit trade comprises 75% of sales. Second, the illegal vape market controlling 70% of U.S. e-cigarette sales directly undermines new categories growth, with vape volumes falling 13% in 2025. Third, the terrorism-related lawsuit from 200 victims seeking unspecified damages adds substantial legal uncertainty beyond the $629 million already paid. The delayed impact of ITC import restrictions until 2027 means near-term relief is unlikely. The thesis requires successful execution on multiple fronts simultaneously: maintaining traditional cigarette profitability despite illicit competition, accelerating Velo adoption to offset vape headwinds, and navigating legal challenges without material additional penalties.
Key Drivers
The primary driver is BAT's strong 2025 financial performance, with pretax profit jumping to £9.86 billion from £3.54 billion and adjusted operating profit rising to £11.89 billion, exceeding analyst expectations. Velo's market share gains in the U.S. nicotine pouch market against competitors represent a critical competitive victory, driven by higher nicotine strengths and promotional offers. The company's pending ITC cases could reduce illegal vape sales by one-third if successful, though implementation delays until 2027 limit near-term impact. Conversely, the South Africa factory closure signals the severity of illicit trade challenges, with 75% market penetration forcing a complete manufacturing exit. The terrorism lawsuit from 200 victims adds material legal risk beyond the $629 million sanctions settlement, potentially exposing BAT to substantial additional damages. Philip Morris's aggressive investment of up to $1.6 billion in Zyn and IQOS intensifies competitive pressure in next-generation products.
Technical Analysis
BATS.L trades at £4,381, exhibiting elevated volatility with a sharp -5.49% decline followed by a +2.94% recovery, now retracing -2.30%. The 5-day decline of -4.95% indicates near-term weakness, while the 1-month gain of +3.33% suggests underlying support. The YTD performance of +3.96% has moderated from the +9.37% peak, establishing a potential resistance zone around £4,600-£4,700. The 6-month performance of +3.37% closely aligns with YTD, indicating limited momentum beyond recent months. Current price action suggests consolidation between £4,300-£4,500, with the stock testing support after failing to sustain post-earnings gains. The -0.52% daily decline reflects continued distribution pressure. Key support appears around £4,350-£4,400, while resistance has formed at £4,600. The pattern suggests a neutral-to-slightly-bearish near-term outlook pending catalyst for directional breakout.
Bull Case
- Exceptional profit growth with pretax profit reaching £9.86 billion versus £3.54 billion prior year, demonstrating robust cash generation capability and operating leverage that exceeded analyst consensus by £600 million
- Velo nicotine pouch gaining U.S. market share against Philip Morris's Zyn, validating competitive strategy through higher nicotine strengths and promotional effectiveness in the fastest-growing tobacco category
- Potential ITC import restrictions could reduce illegal U.S. vape market by one-third, with favorable judge ruling and March determination expected, potentially recovering significant lost volume in the 70% illegal market
- New categories revenue grew 7% at constant currencies to £3.62 billion, demonstrating successful portfolio transformation while maintaining traditional cigarette profitability that funds continued investment
- Dividend increased 2% to 245.04 pence per share, reflecting management confidence in cash generation sustainability and commitment to shareholder returns despite transformation investments
Bear Case
- Terrorism lawsuit from 200 victims seeking unspecified damages beyond $629 million sanctions penalty, exposing BAT to potentially substantial additional liabilities that could materially impact shareholder value and reputation
- South Africa factory closure by year-end due to 75% illicit market penetration, representing complete operational retreat from a key market and signaling vulnerability to illegal trade that could spread to other regions
- Vape volumes fell 13% in 2025 due to illegal products comprising 70% of U.S. e-cigarette sales, directly undermining new categories strategy and offsetting Velo gains with delayed ITC relief until 2027
- Philip Morris investing up to $1.6 billion in Zyn and IQOS with 11-13% EPS growth guidance, intensifying competitive pressure in next-generation products where PMI holds 80% of FDA modified risk authorizations versus BAT's limited approvals
- Revenue declined 1% to £25.61 billion with 3.1% FX headwind, indicating underlying business pressure with 80% revenue concentration in declining traditional cigarettes facing structural volume declines and regulatory constraints